[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-381307-105":59,"doc-detail-381307-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","advancements-in-clinical-aspects-of-targeted-therapy-and-immunotherapy-in-breast-cancer","Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer","","Breast cancer is the second leading cause of death among women worldwide, and its heterogeneity complicates therapeutic management. Molecular and immunological advances have enabled highly targeted treatments by inhibiting specific molecules that drive tumor progression, with several therapies reaching clinical trials and FDA approval for distinct breast cancer forms. Yet effective options remain limited for triple-negative breast cancer (TNBC), where immune-based strategies including checkpoint blockade, vaccination, and adoptive cell transfer are actively studied, including ongoing TNBC trials.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advancements-in-clinical-aspects-of-targeted-therapy-and-immunotherapy-in-breast-cancer/381307/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advancements-in-clinical-aspects-of-targeted-therapy-and-immunotherapy-in-breast-cancer/381307.png","ImageObject",300,407,{"name":92,"@type":93},"Connor ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main goal of targeted therapy in breast cancer?","Question",{"text":113,"@type":114},"Targeted therapy aims to inhibit specific target molecules that support tumor progression. Approaches include targeting pathways relevant to particular breast cancer subtypes.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why is triple-negative breast cancer (TNBC) considered challenging?",{"text":118,"@type":114},"Targeted drugs have not yet achieved strong therapeutic promise against TNBC, and the disease’s heterogeneity continues to present major clinical challenges.",{"name":120,"@type":111,"acceptedAnswer":121},"Which immunotherapy modalities are highlighted for breast cancer, especially TNBC?",{"text":122,"@type":114},"The text highlights immune-checkpoint blockade, vaccination, and adoptive cell transfer. It also notes that some immune-checkpoint blockers are approved in combination with chemotherapeutic drugs for TNBC and that additional trials are ongoing.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},381307,1790512892,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":36,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},687207022233,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Ye etal. Molecular Cancer (2023) 22:105 [https://doi.org/10.1186/s12943-023-01805-y](https://doi.org/10.1186/s12943-023-01805-y)  \nMolecular Cancer  \n REVIEW Open Access  \nAdvancements in clinical aspects of targeted   therapy and immunotherapy in breast cancer  \nFeng Ye1, Saikat Dewanjee2, Yuehua Li3,4†, Niraj Kumar Jha5,6, Zhe‑Sheng Chen7, Ankush Kumar8, Vishakha8, Tapan Behl9*†, Saurabh Kumar Jha5,10,11* and Hailin Tang1*  \nAbstract  \nBreast cancer is the second leading cause of death for women worldwide. The heterogeneity of this disease presentsa big challenge in its therapeutic management. However, recent advances in molecular biology and immunology enable to develop highly targeted therapies for many forms of breast cancer. The primary objective of targeted ther‑ apy is to inhibit a specific target/molecule that supports tumor progression. Ak strain transforming, cyclin‑dependent kinases, poly (ADP‑ribose) polymerase, and different growth factors have emerged as potential therapeutic targets for specific breast cancer subtypes. Many targeted drugs are currently undergoing clinical trials, and some have already received the FDA approval as monotherapy or in combination with other drugs for the treatment of different forms of breast cancer. However, the targeted drugs have yet to achieve therapeutic promise against triple‑negative breast cancer (TNBC). In this aspect, immune therapy has come up as a promising therapeutic approach specifically forTNBC patients. Different immunotherapeutic modalities including immune‑checkpoint blockade, vaccination, and adoptive cell transfer have been extensively studied in the clinical setting of breast cancer, especially inTNBC patients. The FDA has already approved some immune‑checkpoint blockers in combination with chemotherapeutic drugs to treat TNBC and several trials are ongoing. This review provides an overview of clinical developments and recent advancements in targeted therapies and immunotherapies for breast cancer treatment. The successes, challenges, and prospects were critically discussed to portray their profound prospects.  \nKeywords Breast cancer, Clinical trials, Immune‑checkpoint Inhibitors, Immunotherapy, Targeted therapies  \n†Yuehua Li and Tapan Behl contributed equally to this work.  \n*Correspondence:  \nTapan Behl[tapanbehl31@gmail.com](tapanbehl31@gmail.com)[ ](tapanbehl31@gmail.com)Saurabh Kumar Jha [Saurabh.jha@sharda.ac.in](Saurabh.jha@sharda.ac.in)[ ](Saurabh.jha@sharda.ac.in)Hailin Tang [tanghl@sysucc.org.cn](tanghl@sysucc.org.cn)  \n1 State Key Laboratory of Oncology in South China, SunYat‑Sen University Cancer Center, Guangzhou, China  \n2 Advanced Pharmacognosy Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, India  \n3 Department of Medical Oncology, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China  \n4 Institute of Pathogenic Biology, Hengyang Medical College, University of South China, Hengyang, China  \n5 Department of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida, India  \n6 School of Bioengineering & Biosciences, Lovely Professional University, Phagwara 144411, India  \n7 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, New York 11439, USA  \n8 Pharmaceutical and Health Sciences, Career Point University, Hamirpur, Himachal Pradesh, India  \n9 School of Health Sciences and Technology, University of Petroleum and Energy Studies, Bidholi, Dehradun, Uttarakhand, India  \n10 Department of Biotechnology Engineering and Food Technology, Chandigarh University, Mohali 140413, India  \n11 Department of Biotechnology, School of Applied & Life Sciences (SALS), Uttaranchal University, Dehradun 248007, India  \n© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and","cbCaih7SJmgIVq7g","https://ap.wps.com/l/cbCaih7SJmgIVq7g","pdf",3111257,"English","# Abstract\n# Introduction","[{\"question\":\"What is the main goal of targeted therapy in breast cancer?\",\"answer\":\"Targeted therapy aims to inhibit specific target molecules that support tumor progression. Approaches include targeting pathways relevant to particular breast cancer subtypes.\"},{\"question\":\"Why is triple-negative breast cancer (TNBC) considered challenging?\",\"answer\":\"Targeted drugs have not yet achieved strong therapeutic promise against TNBC, and the disease’s heterogeneity continues to present major clinical challenges.\"},{\"question\":\"Which immunotherapy modalities are highlighted for breast cancer, especially TNBC?\",\"answer\":\"The text highlights immune-checkpoint blockade, vaccination, and adoptive cell transfer. It also notes that some immune-checkpoint blockers are approved in combination with chemotherapeutic drugs for TNBC and that additional trials are ongoing.\"}]","Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer | PDF",1790244770,101]